Weekly Analysts’ Ratings Changes for Beta Bionics (BBNX)

A number of research firms have changed their ratings and price targets for Beta Bionics (NASDAQ: BBNX):

• 2/24/2025 – Beta Bionics was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 2/24/2025 – Beta Bionics is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $26.00 price target on the stock.
• 2/24/2025 – Beta Bionics is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $28.00 price target on the stock.
• 2/24/2025 – Beta Bionics is now covered by analysts at Bank of America Co.. They set a “buy” rating on the stock.
• 2/24/2025 – Beta Bionics is now covered by analysts at Lake Street Capital. They set a “buy” rating and a $30.00 price target on the stock.
• 2/24/2025 – Beta Bionics is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $25.00 price target on the stock.
• 2/20/2025 – Beta Bionics is now covered by analysts at LADENBURG THALM/SH SH. They set a “neutral” rating and a $20.00 price target on the stock.
• 2/20/2025 – Beta Bionics is now covered by analysts at Robert W. Baird. They set a “neutral” rating and a $20.00 price target on the stock.
• 2/20/2025 – Beta Bionics was upgraded by analysts at Baird R W to a “hold” rating.

Beta Bionics Trading Down 11.6 %

Shares of NASDAQ:BBNX traded down $2.44 during trading on Tuesday, hitting $18.54. The company’s stock had a trading volume of 444,428 shares, compared to its average volume of 330,238. Beta Bionics, Inc. has a 12 month low of $17.36 and a 12 month high of $24.50.

Insider Buying and Selling at Beta Bionics

In related news, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the company’s stock in a transaction on Friday, January 31st. The stock was acquired at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the acquisition, the insider now directly owns 3,901,599 shares of the company’s stock, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, insider Mike Mensinger acquired 33,350 shares of Beta Bionics stock in a transaction on Friday, January 31st. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the purchase, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. The trade was a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.